all report title image

VERTEPORFIN MARKET ANALYSIS

Verteporfin Market, by Indication (Macular Degeneration, Pathological Myopia, and Ocular Histoplasmosis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI4154
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Challenges And Opportunities

Global Verteporfin Market: Restraints

According to the National Library of Medicine, photo dynamic treatment with verteporfin is costlier than pegaptinib for treatment of sub-foveal wet macular degeneration in elderly patients. The cost of pegatanib is US$ 49,052 compared to cost of photo dynamic treatment with verteporfin which is US$ 59,039 in U.S. Moreover, verteporfin is given intravenously before treatment which can cause infection at site of injection such as irritation, redness of skin etc. These factors are expected to restrain the growth of global verteporfin market.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.